Aethlon Medical, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended March 31, 2023, compared with fiscal year ended March 31, 2022. The filing does not provide separate fourth-quarter results; the “2022 Q4” request metadata does not match the annual reporting period. Aethlon is a clinical-stage medical-device company developing its Hemopurifier for cancer and life-threatening viral diseases. The financial statements received an unqualified audit opinion.
Financial results and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue, entirely government contracts and grants | $574,245 | $294,165 |
| Operating expenses | $12,472,883 | $10,715,050 |
| Operating loss | $(11,898,638) | $(10,420,885) |
| Net loss attributable to common stockholders | $(12,029,786) | $(10,416,091) |
| Basic and diluted loss per share | $(0.59) | $(0.71) |
| Net cash used in operating activities | $(10,505,128) | $(9,767,157) |
| Net cash used in investing activities | $(943,109) | $(349,193) |
| Net cash provided by financing activities | $8,914,718 | $17,367,974 |
- Revenue increased by $280,080, but remained small relative to operating costs. Revenue came from NIH contracts and grants; the principal Phase II NCI contract ended September 15, 2022.
- Operating expenses rose $1.76 million, primarily from higher general and administrative expenses and professional fees. Research and development costs were approximately $2.745 million, up from $2.341 million.
- Cash and cash equivalents were $14.53 million at March 31, 2023, down from $17.07 million. Working capital was $13.59 million, versus $16.33 million.
- Total assets were $17.51 million and total liabilities were $2.44 million. The filing reports no convertible notes or derivative instruments at year-end; liabilities principally include operating lease obligations. Lease liabilities totaled approximately $1.21 million.
- Management stated that cash at March 31, 2023, together with funds raised afterward, was expected to fund operations for at least 12 months from the financial-statement issuance date. The company also expects continued losses, negative operating cash flow and a need for additional capital.
Material changes and financing
- The net loss increased from approximately $10.42 million to $12.03 million, while operating cash use increased by approximately $738,000.
- FY2023 financing was principally through the 2022 at-the-market (ATM) equity program: 7,480,836 shares sold for net proceeds of $8.93 million, at an average price of $1.19 per share. Common shares outstanding increased from 15.42 million to 22.99 million during the year.
- After year-end, the company sold 1,778,901 additional shares under the ATM for net proceeds of approximately $1.09 million at an average price of $0.61 per share. The filing reports 24,771,367 common shares outstanding as of June 26, 2023.
- The company dissolved its majority-owned subsidiary, Exosome Sciences, Inc., in September 2022 and recorded a $142,121 loss on dissolution.
Business outlook, risks and notable items
- The Hemopurifier has FDA Breakthrough Device designations for certain advanced or metastatic cancers and for life-threatening viruses without approved therapies. These designations are not marketing approvals and do not ensure faster review or eventual approval.
- The company is preparing oncology clinical trials in Australia with NAMSA, a clinical research organization. Its prior U.S. head-and-neck cancer study treated two patients and was terminated after further enrollment could not be achieved. A U.S. COVID-19 feasibility study was also terminated in 2022 because trial sites lacked ICU patients meeting study criteria.
- Manufacturing and U.S. trial activity face a supply disruption: existing Hemopurifiers expired September 30, 2022, and the company was awaiting FDA approval for a new GNA supplier. The filing says 112 devices had passed quality control but could not be shipped for domestic use pending approval. Supplier qualification and reliance on limited sources for key components remain risks.
- India clinical work has ERB approval at Medanta, where one patient completed participation; a second site received ERB approval in May 2023. The company also began exploratory translational work on potential organ-transplant applications; this is not described as an established clinical program.
- Key risks include ongoing losses and reliance on further financing; clinical, regulatory and enrollment uncertainty; manufacturing and supplier delays; competition; possible dilution; and Nasdaq listing compliance. Nasdaq granted an extension through October 23, 2023 to regain the $1.00 minimum bid-price requirement.
- Management cited inflation, bank failures and the war in Ukraine as sources of uncertainty for capital access and operating plans. No quantitative earnings or revenue guidance was provided.
- The company reported no pending legal proceedings. Management concluded disclosure controls and internal control over financial reporting were effective as of March 31, 2023; the auditor did not provide an opinion on internal controls.
Important facts for investors to verify
- Current cash, operating burn, runway and the terms and remaining capacity of any equity financing; assess dilution from ATM sales and equity awards.
- Whether FDA approval for the new GNA supplier was obtained, and whether Hemopurifier production and U.S. clinical use resumed.
- Timing, enrollment, protocols and results for planned Australia oncology studies and ongoing India studies; distinguish clinical evidence from in-vitro findings and individual case reports.
- Nasdaq listing status and compliance with all continued-listing requirements.
- Whether new grants, partnerships or other funding replace revenue from the expired NCI contract, and whether the company can finance operations beyond management’s stated 12-month outlook.